ATE408400T1 - Pharmazeutische zusammensetzung mit verzögerter freisetzung - Google Patents

Pharmazeutische zusammensetzung mit verzögerter freisetzung

Info

Publication number
ATE408400T1
ATE408400T1 AT02076991T AT02076991T ATE408400T1 AT E408400 T1 ATE408400 T1 AT E408400T1 AT 02076991 T AT02076991 T AT 02076991T AT 02076991 T AT02076991 T AT 02076991T AT E408400 T1 ATE408400 T1 AT E408400T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
delayed release
release pharmaceutical
formulation
drug
Prior art date
Application number
AT02076991T
Other languages
English (en)
Inventor
Inger Norden
Peter Fyhr
Catarina Carling
Original Assignee
Watson Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Lab Inc filed Critical Watson Lab Inc
Application granted granted Critical
Publication of ATE408400T1 publication Critical patent/ATE408400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02076991T 2002-05-21 2002-05-21 Pharmazeutische zusammensetzung mit verzögerter freisetzung ATE408400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02076991A EP1364644B1 (de) 2002-05-21 2002-05-21 Pharmazeutische Zusammensetzung mit verzögerter Freisetzung

Publications (1)

Publication Number Publication Date
ATE408400T1 true ATE408400T1 (de) 2008-10-15

Family

ID=29286190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02076991T ATE408400T1 (de) 2002-05-21 2002-05-21 Pharmazeutische zusammensetzung mit verzögerter freisetzung

Country Status (4)

Country Link
EP (1) EP1364644B1 (de)
AT (1) ATE408400T1 (de)
DE (1) DE60228939D1 (de)
ES (1) ES2312525T3 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432254B (zh) * 2021-12-30 2023-05-16 南通联亚药业股份有限公司 一种硝苯地平控释片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity

Also Published As

Publication number Publication date
EP1364644B1 (de) 2008-09-17
ES2312525T3 (es) 2009-03-01
DE60228939D1 (de) 2008-10-30
HK1062632A1 (en) 2004-11-19
EP1364644A1 (de) 2003-11-26

Similar Documents

Publication Publication Date Title
SE0004671D0 (sv) Pharmaceutical formulation
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
DE60232496D1 (de) Tabletten, die in der mundhöhle schnell zerfallen
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
CU23440B7 (es) Composición de liberación sostenida de pramipexol
CL2004000837A1 (es) Pelicula ingerible para adherirse y disolverlo en la cavidad oral, que comprende un polimero soluble en agua, un enmascarador de sucralosa y un agente farmaceuticamente activo.
WO2003018075A3 (de) Transdermales therapeutisches system mit fentanyl bzw. verwandten substanzen
ES2037082T3 (es) Una composicion para la liberacion controlada de un farmaco.
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
NO20024919D0 (no) Hydrofil/lipofil polymer matriksdoseringsformulering
BR9912066A (pt) Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
DE60128263D1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
BG108870A (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
DE60228939D1 (de) Pharmazeutische Zusammensetzung mit verzögerter Freisetzung
SE0001916D0 (sv) Novel formulation
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
AR044983A1 (es) Solidos con capa de difusion modulada
WO2001022917A3 (en) Effervescent compositions comprising nimesulide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee